Physicians Committee for Responsible Medicine, A Randomized, Crossover Trial of the Effect of a Dietary Intervention on Intracellular Lipid, Insulin Sensitivity, and Glycemic Control in Type 2 Diabetes
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Diabetes Mellitus, Type 2
- Sponsor
- Physicians Committee for Responsible Medicine
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- Intramyocellular lipid content
- Status
- Withdrawn
- Last Updated
- 10 months ago
Overview
Brief Summary
The purpose of this study is to compare the effects of a low-fat, plant-based dietary intervention and a portion-controlled dietary intervention (compliant with current American Diabetes Association (ADA) guidelines) on changes in intramyocellular and hepatocellular lipid content in adults with type 2 diabetes. Changes in insulin sensitivity and glycemic control will also be assessed in this study. The study duration is 44 weeks.
Detailed Description
Type 2 diabetes is a disease characterized by discordance between the amount of insulin produced by pancreatic β-cells and the amount of insulin required to overcome insulin resistance in the liver and peripheral tissues. The development of insulin resistance has been strongly associated with the prolonged accumulation of lipids (fats) in the liver cells ("hepatocellular lipid") and muscle cells ("intramyocellular lipid"). Conventional pharmacologic therapeutics for type 2 diabetes, like metformin, are designed to reduce the accumulation of hepatocellular and intramyocellular lipids and, thereby, augment insulin sensitivity. Research has shown that a low-fat, plant-based diet, in which the consumption of lipids is limited, is a similarly effective therapeutic intervention for the reduction of hepatocellular and intramyocellular lipid content and the improvement of insulin sensitivity in type 2 diabetes. The purpose of this study is to compare the effects of low-fat, plant-based dietary intervention and a portion-controlled dietary intervention (compliant with current American Diabetes Association (ADA) guidelines) on hepatocellular and intramyocellular lipid content in adults with type 2 diabetes. Using a cross-over design, participants with type 2 diabetes will be randomly assigned to start with a plant-based or a portion-controlled diet for 22 weeks. The two groups will then switch to the opposite diet regimen for an additional 22 weeks. Before and after each intervention period, the investigators will measure intramuscular and liver fat content. The investigators will also assess the relationship between these variables, insulin sensitivity, and glycemic control. The investigators hypothesize that both dietary interventions will result in reductions in intramuscular and liver fat content, and that these changes will be associated with improvements in insulin sensitivity and glycemic control in individuals with type 2 diabetes. The investigators further hypothesize that the low-fat, plant-based dietary intervention will elicit greater changes in intracellular lipid concentration, compared with the portion-controlled dietary intervention.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Intramyocellular lipid content
Time Frame: 1.) Change from week 0 to week 22; 2.) Change from week 22 to week 44
Proton magnetic resonance (MR) spectroscopy at 4T (Bruker) will be implemented to quantify intramyocellular lipid concentrations.
Hepatocellular lipid content
Time Frame: 1.) Change from week 0 to week 22; 2.) Change from week 22 to week 44
Proton magnetic resonance (MR) spectroscopy at 4T (Bruker) will be implemented to quantify intramyocellular lipid concentrations.
Insulin sensitivity
Time Frame: Change from baseline to 22 weeks and change from 22 weeks to 44 weeks
Insulin resistance will be assessed by the Homeostatic Model Assessment (HOMA) PREDIM indexes
Concentration of glucose
Time Frame: 1.) Change from week 0 to week 22; 2.) Change from week 22 to week 44
Concentration of glucose will be assessed during a standard meal test (Boost Plus, Nestle, Vevey, Switzerland; 720 kcal, 34% of energy from fat, 16% protein, 50% carbohydrate). Plasma concentrations of glucose will be measured at 0, 30, 60, 120, and 180 min.
Concentration of C-peptide
Time Frame: 1.) Change from week 0 to week 22; 2.) Change from week 22 to week 44
Concentration of C-peptide be assessed during a standard meal test (Boost Plus, Nestle, Vevey, Switzerland; 720 kcal, 34% of energy from fat, 16% protein, 50% carbohydrate). Concentration of C-peptide will be measured at 0, 30, 60, 120, and 180 min.
Rate of glycemic control
Time Frame: 1.) Change from week 0 to week 22; 2.) Change from week 22 to week 44
Rate of glycemic control will be assessed through HbA1C.
Secondary Outcomes
- Resting energy expenditure(Change from baseline to 22 weeks and change from 22 weeks to 44 weeks)
- Concentration of plasma lipids(Change from baseline to 22 weeks and change from 22 weeks to 44 weeks)
- Body weight(Change from baseline to 22 weeks and change from 22 weeks to 44 weeks)
- Gut microbiome composition(Change from baseline to 22 weeks and change from 22 weeks to 44 weeks)
- Postprandial metabolism(Change from Baseline to 22 weeks and change from 22 weeks to 44 weeks)
- Body Composition(Change from baseline to 22 weeks and change from 22 weeks to 44 weeks)